India Chronic Inflammatory Demyelinating Polyneuritis Therapeutics Market Analysis
India Chronic Inflammatory Demyelinating Polyneuritis Therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. A acquired immune-mediated neuropathy that affects peripheral nerves and nerve roots, chronic inflammatory demyelinating polyneuropathy (CIDP; also known as chronic inflammatory demyelinating polyradiculoneuropathy) is characterised by a progressive or relapsing-remitting course of symmetric weakness of the proximal and distal muscles. Growing government spending and disease awareness have been the market's main drivers for Chronic Inflammatory Demyelinating Polyneuritis (CIDP) Therapeutics. Bio products laboratory Ltd., Momenta Pharmaceuticals, Grifols, Baxter, Octapharma, Shire, Kedrion SPA, Misubishi Tanabe Pharma Corporation, CSL Behring, and Teijin Pharma Ltd. are global firms in the Chronic Inflammatory Demyelinating Polyneuritis (CIDP) Therapeutics market.
Buy Now
India Chronic Inflammatory Demyelinating Polyneuritis Therapeutics Market Analysis Summary
India Chronic Inflammatory Demyelinating Polyneuritis Therapeutics Market is valued at around $29.46 Mn in 2022 and is projected to reach $65.49 Mn by 2030, exhibiting a CAGR of 10.5% during the forecast period 2023-2030.
An acquired immune-mediated neuropathy that affects peripheral nerves and nerve roots, chronic inflammatory demyelinating polyneuropathy (CIDP; also known as chronic inflammatory demyelinating polyradiculoneuropathy) is characterized by a progressive or relapsing-remitting course of the symmetric weakness of the proximal and distal muscles. Electrodiagnostic and/or pathologic signs of demyelination, as well as responsiveness to immunomodulatory therapies, are used to diagnose CIDP. Segmental demyelination and remyelination of peripheral nerves, which may lead to onion bulb development, are among the distinctive pathologic hallmarks of CIDP. "Onion bulb formation" describes how the damaged axons appear when seen in a transverse section under a microscope. Because of whorls of overlapping and proliferating Schwann cell processes enclosing exposed axons, damaged nerve fibres become larger as a result of recurrent bouts of demyelination and remyelination. Patchy nerve involvement with uneven involvement along a nerve's length is common. Demyelination frequently takes place paranodal, close to Ranvier nodes. Microscopically, lymphocytes and macrophages are present in endoneurial inflammatory cell infiltrates in varying degrees. It is believed that the macrophages start the demyelination process by tearing up and deteriorating myelin. However, the majority of clinical biopsy specimens do not include many macrophages. CIDP is largely a demyelinating condition, but there is frequently some axonal degeneration as well. Axonal degeneration in CIDP has not been fully understood, but it has been assumed that it is a secondary bystander effect of the inflammatory demyelinating process. Clinically, CIDP is divided into "typical" and "atypical" cases; typical CIDP is a symmetrical polyneuropathy that affects proximal and distal muscles equally, whereas atypical CIDP includes "distal acquired demyelinating symmetric" (DADS) and multifocal acquired demyelinating sensory and motor neuropathy. At least 50 to 60 per cent of all cases are of the most prevalent subtype of CIDP, known as typical CIDP. Muscle weakening in the proximal and distal regions that outweighs sensory loss is a hallmark of typical CIDP, which is characterized by a sensorimotor polyneuropathy that is rather symmetric.
The market for Chronic Inflammatory Demyelinating Polyneuritis (CIDP) Therapeutics has shown signs of growth due to rising disease awareness and government funding.
Bio Products Laboratory Ltd., Momenta Pharmaceutical, Baxter, Octapharma, AbbVie, Shire, ADMA biologics, Grifols, Kedrion SPA, Mitsubishi Tanabe Pharma Corporation, Pfizer, CSL Behring, and Teijin Pharma Ltd. are some of the major international players in the Chronic Inflammatory Demyelinating Polyneuritis (CIDP) Therapeutics market.
Market dynamics
Market Drivers
The rising incidence of CIDP led to increasing R&D spending as well as strategic alliances between pharmaceutical and research organizations. The market for chronic inflammatory demyelinating polyneuritis therapeutics in [country name] is driven by all of these factors taken combined.
Market Developments
Nipocalimab is currently in Phase III of clinical development by Johnson & Johnson for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). The market for therapeutics for chronic inflammatory demyelinating polyneuritis is currently developing immunoglobulin treatment. The use of intravenous immune globulin (IVIG) for CIDP and a brief improvement in leg CRPS was successful.
Restraints in the Chronic Inflammatory Demyelinating Polyneuritis Therapeutics market
The Chronic Inflammatory Demyelinating Polyneuritis Therapeutics market offers expensive medications that not everyone can afford. Additionally, there is currently a dearth of effective treatments for Chronic Inflammatory Demyelinating Polyneuritis.
Key players
Biogen Inc. Novartis AG Sanofi Teva Pharmaceutical Industries Ltd. EMD Serono Genzyme Acorda Therapeutics Inc. Alkermes plc Momenta Pharmaceuticals Inc. Catalyst Biosciences Inc.1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country
2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)
3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints
4. Competitive Landscape
4.1 Major Market Share
4.2 Key Company Profile (Check all Companies in the Summary Section)
4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)
5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment
6. Methodology and Scope
Market segmentations for India Chronic Inflammatory Demyelinating Polyneuritis Therapeutics market
By type
- Multifocal CIDP
- Focal CIDP
- Motor CIDP
- Sensory CIDP
- Distal CIDP
By treatment
By drug type
- Corticosteroids
- Immunoglobin
- Other
By diagnosis
- Electrodiagnostic testing
- Neurologic
- EMG
- Cerebrospinal Fluid Analysis
- Laboratory tests
- Fasting serum glucose and/or oral glucose tolerance test
- Glycated haemoglobin (HbA1C)
- Serum calcium and creatinine
- Complete blood count
- Liver function tests
- Thyroid function studies
- Serum protein electrophoresis (SPEP) and immunofixation
- Serum-free light chain (FLC) assay
- Other tests – Neuroimaging, Nerve ultrasound, Role of treatment trial, and many more.
By route of administration
- Oral
- Injectable
- Other
By distribution channel
- Hospital
- Pharmacy
- Clinics
- Others
Methodology for Database Creation
Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.
Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.
How Do We Get It?
Our database is created and maintained through a combination of secondary and primary research methodologies.
1. Secondary Research
With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:
- Analyzing historical proprietary data collected from multiple projects.
- Regularly updating our existing data sets with new findings and trends.
- Ensuring data consistency and accuracy through rigorous validation processes.
With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:
- Searching through academic conferences, published research, citations, and social media platforms
- Collecting and compiling diverse data to build a comprehensive and detailed database
- Continuously updating our database with new information to ensure its relevance and accuracy
2. Primary Research
To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:
- Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
- Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
- Continuously refreshing our database to ensure that the information remains current and reliable.
- Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.
Combining Secondary and Primary Research
By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:
- Merging historical data from secondary research with real-time data from primary research.
- Conducting thorough data validation and cleansing to remove inconsistencies and errors.
- Organizing data into a structured format that is easily accessible and usable for various applications.
- Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.
Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.
To request a free sample copy of this report, please complete the form below.
We value your inquiry and offer free customization with every report to fulfil your exact research needs.
Related reports (by category)
Germany Wilson's Disease Drugs Market Analysis
Spain Colorectal Cancer Therapeutics Market Analysis
Related reports (by geography)
India Erythropoietin Drugs Market Analysis
India Financial Assistance Programs Market Analysis
